Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database-Reference-Cited by-同舟云学术

Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

Published:2021-01-13 Issue:2 Volume:35 Page:239-254
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Tanni Kaniz Afroz^ORCID,Truong Cong Bang^ORCID,Almahasis Sura^ORCID,Qian Jingjing^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-020-00466-3.pdf

Reference60 articles.

1. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines & #x2020. Ann Oncol. 2016;27:v111–8. https://doi.org/10.1093/annonc/mdw325.

2. Tai E Jr., Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–61. https://doi.org/10.1200/jop.2016.019588.

3. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–306. https://doi.org/10.1016/j.ejca.2004.06.019.

4. Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010–2013. Clin Epidemiol. 2016;8:61–71. https://doi.org/10.2147/CLEP.S89480.

5. Family L. Symptom burdens related to chemotherapy-induced anemia in stage IV cancer. J Community Support Oncol. 2018;16(6):e260–71. https://doi.org/10.12788/jcso.0432.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model driven method for exploring individual and confounding effects in spontaneous adverse event reporting databases;Expert Opinion on Drug Safety;2023-12-11

2. Safety of Adalimumab: An Analysis of the FDA Adverse Event Reporting System (FAERS) Database;Jordan Journal of Pharmaceutical Sciences;2023-09-23

3. Movement disorders associated with antiseizure medications: A real‐world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System;British Journal of Clinical Pharmacology;2023-07-18

4. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States;Expert Opinion on Biological Therapy;2023-03-09

5. Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells in Safety Pharmacology;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2022